Assessment of Diagnostic Accuracy and Performance of Digital Breast Tomosynthesis Compared to Mammography (ADAPT)

Assessment of Diagnostic Accuracy and Performance of Digital Breast Tomosynthesis Compared to Mammography (ADAPT Trial) ADAPT-BX: Recruitment Plan for Initially Asymptomatic Women Referred for Breast Biopsy

Status

Terminated

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT02324205

Acronym

ADAPT

Enrollment

196

Registered

2014-12-24

Start date

2015-03-31

Completion date

2017-08-29

Last updated

2019-02-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast Cancer, Tumors, Breast

Brief summary

The aim of this recruitment plan (ADAPT-BX) is to collect image and technical data on both digital breast tomosynthesis (DBT) and full-field digital mammography (FFDM), along with other subject data including histology results from biopsy specimen examination and cancer classification data from initially asymptomatic women referred for biopsy after recall from screening and diagnostic work-up. These data will be included in a subsequent and prospectively planned pooled analysis described in a separate protocol (ADAPT-BIE) examining superiority of DBT to FFDM for breast cancer diagnosis and other clinical performance measures.

Detailed description

ADAPT program consists of 2 recruitment plans (ADAPT-SCR and ADAPT-BX) followed by an off-line read of the images and data collected (ADAPT-BIE). This study involves the comparison of two devices that can identify abnormalities in routine breast screening and diagnostic mammography. Mammography is usually done with full-field digital mammography (FFDM), which takes flat, two-dimensional X-ray images of the breast. Doctors use the two-dimensional images to look for cancers and other abnormal tissue. The purpose of this study is to learn more about the accuracy of full-field digital mammography devices and a new mammography device called digital breast tomosynthesis (DBT). DBT is similar to full-field digital mammography, but can also move around the breast to get X-ray images from different angles, which provides a three-dimensional view that doctors can use to look for cancers and abnormal tissue. Subjects will be recruited from an initially asymptomatic population that have been referred for clinically indicated breast biopsy based on suspicious breast imaging results. Subjects will undergo a DBT mammogram prior to biopsy. If FFDM was not performed within 30 days, subjects will also undergo FFDM prior to biopsy. Results of biopsy(ies) and histopathology, including lesion characteristics, will be recorded and considered as truth if positive for cancer status. Subjects with negative or benign histological findings will be followed for approximately one year (10-16 months) by FFDM and any additional standard of care practice.

Interventions

DEVICEDBT and FFDM

Subjects underwent breast imaging using each device: DBT and FFDM.

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

DIAGNOSTIC

Masking

NONE

Intervention model description

All participants underwent 2D breast imaging with Full-field digital mammography (FFDM) and by 3D breast imaging with Digital Breast Tomosynthesis (DBT).

Eligibility

Sex/Gender

FEMALE

Age

30 Years to No maximum

Healthy volunteers

Inclusion criteria

* Women aged 30 years or older (≥30 years old); * Initially asymptomatic women that underwent routine screening FFDM, breast ultrasound (U/S), breast magnetic resonance imaging (MRI) and/or DBT, followed by diagnostic work-up showing one of more abnormalities and referred for breast biopsy within of 30 days before study entry; * Are able and willing to comply with study procedures; * Have signed and dated the informed consent form; * Documented as non-pregnant based on the investigator's medical judgment and in consideration of local clinical practice standards for evidence of non-pregnancy.

Exclusion criteria

* Have been previously included in this study; * Have undergone diagnostic or surgical intervention(s) or procedure(s) on either breast, including mastectomy and cytopunction, before study-related imaging; * Have breasts too large to be adequately positioned on 24 x 31 centimeter (cm) FFDM digital receptor without anatomical cut off during a DBT examination (or FFDM, if required); * Have participated in (within the prior 30 days), another trial of an investigational product expected to interfere with study procedures or outcomes; * Have breast implant(s); * Have reconstructed breast(s).

Design outcomes

Primary

Measure	Time frame	Description
Number of Participants With DBT, FFDM and Biopsy Specimens Collected.	Approximately 8 weeks	For each participant, obtain image data using two methods (DBT and FFDM) and obtain histology results of biopsy specimens from women referred for biopsy.

Secondary

Measure	Time frame	Description
Lesion Type Observed by FFDM Imaging	Approximately 8 weeks	Lesions were characterized based on findings identified during image evaluations performed by qualified readers.
Lesion Type Observed by DBT Imaging	Approximately 8 weeks	Lesions were characterized based on findings identified during image evaluations performed by qualified researchers.
Maximum Lesion Dimension as Observed by DBT	Approximately 8 weeks	Maximum length of lesions (measured in mm) when images were collected using DBT
Biopsy Finding of Lesions Per Subject.	Approximately 8 weeks	Describes histologic cancer and non-cancer findings of lesion biopsy. Cancer status of lesions was reported per subject, not per lesion.
Maximum Lesion Dimension as Observed by FFDM	Approximately 8 weeks	Maximum Length of Lesions (measured in mm) when images were collected using FFDM.

Other

Measure	Time frame	Description
Safety - Device Related Malfunctions	less than 16 months	Number of device-related malfunctions by imaging modality.

Countries

France, United States

Participant flow

Participants by arm

Arm	Count
DBT and FFDM Subjects underwent 2D breast imaging with full-field digital mammography (FFDM) followed by 3D breast imaging with digital breast tomosynthesis (DBT). Digital Breast Tomosynthesis: 3D imaging of the breast using Digital Breast Tomosynthesis (DBT) device. Full-Field Digital Mammography: 2D imaging of the breast using Full-Field Digital Mammography (FFDM) device. DBT and FFDM: Subjects underwent breast imaging using each device: DBT and FFDM.	196
Total	196

Arm

Count

DBT and FFDM

Subjects underwent 2D breast imaging with full-field digital mammography (FFDM) followed by 3D breast imaging with digital breast tomosynthesis (DBT). Digital Breast Tomosynthesis: 3D imaging of the breast using Digital Breast Tomosynthesis (DBT) device. Full-Field Digital Mammography: 2D imaging of the breast using Full-Field Digital Mammography (FFDM) device. DBT and FFDM: Subjects underwent breast imaging using each device: DBT and FFDM.

196

Total

196

Withdrawals & dropouts

Period	Reason	FG000
Overall Study	Withdrawal by Subject	37

Baseline characteristics

Characteristic	DBT and FFDM	—
Age, Customized Age 30 years and greater	196 Participants	—
Race and Ethnicity Not Collected	—	— Participants
Region of Enrollment France	60 Participants	—
Region of Enrollment United States	136 Participants	—
Sex: Female, Male Female	196 Participants	—
Sex: Female, Male Male	0 Participants	—

Adverse events

Event type	EG000 affected / at risk
deaths Total, all-cause mortality	0 / 196
other Total, other adverse events	0 / 196
serious Total, serious adverse events	0 / 196

Outcome results

Primary

Number of Participants With DBT, FFDM and Biopsy Specimens Collected.

For each participant, obtain image data using two methods (DBT and FFDM) and obtain histology results of biopsy specimens from women referred for biopsy.